Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Azacitidine in Chinese Patients With Higher-Risk MDS
NCT01599325Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Jul 2012; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01599325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01599325.